MAC2v3 Study Results

Posted by june72 @june72, Jun 17 6:48am

Hi,
I have attempted to find out when the final results for the MAC2v3 study may be posted but have been unsuccessful. I did contact the main provide at Oregon Health, but no response.
Is anyone else following this, any suggestions? The study concluded for the data collection in November 2025.
Thanks, Ronni

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

I am new to this group and just diagnosed with MAC. My pulmonologist said I can drink water from my home as I have been. I am on a public water supply. Any thoughts on this?

REPLY
Profile picture for galec @galec

I am new to this group and just diagnosed with MAC. My pulmonologist said I can drink water from my home as I have been. I am on a public water supply. Any thoughts on this?

Jump to this post

@galec
Give this a read. Each one of us makes our own determinations about how much risk to take. Every circumstance is different. The common denominator is that we have bronchiectasis.

Shared files

Reducing Exposure to Nontuberculous Mycobacteria (Reducing-Exposure-to-Nontuberculous-Mycobacteria.pdf)

REPLY

@june72 It typically takes 9-12 months after data collection ends to gather all the results, analyze, write the report and have it reviewed, so I would guess we have to wait until autumn to hear anything.

REPLY

@june72 I don’t believe the results on the 2v3 study that closed in 2025 have been published yet. However the results were announced at the ATS conference this spring, and discussed at NTMir’s patient conference around the same time. Prof. Chalmers discussed the results as part of a recent presentation for Running on Air. I think the 2v3 study needs to be read together with the study that recently concluded re Arikayce as a front line drug (not sure if these are published yet either, believe it is the Aspen study). My NJH doctor told me that three drugs still seems to provide the best chance at conversion but the Big 3 in the future will likely be azithromycin, ethambutol and Arikayce, as conversion rates were far higher with Arikayce as the third drug (over rifampin). What was surprising to me about the 2v3 study is just how low the conversion rates were for both groups. And my recollection is that the 2v3 study excluded anyone with cavitary disease so these were all patients with only nodular bronchiectatic disease. Even as someone who has had a lot of issues with Arikayce, I hope it soon becomes widely available as a front line drug for MAC patients. Everyone deserves a fighting chance.

REPLY
Profile picture for scoop @scoop

@galec
Give this a read. Each one of us makes our own determinations about how much risk to take. Every circumstance is different. The common denominator is that we have bronchiectasis.

Jump to this post

@scoop Thank you. This is complicated, and I do have bronchiectasis as well.

REPLY
Please sign in or register to post a reply.